Medicine
Lincocin 600 mg/2 mL injection
Lincocin 600 mg/2 mL injection is a prescription medicine containing Lincomycin for intramuscular, intravenous, subconjunctival use, marketed by Pharmacia & Upjohn, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature 20° to 25°C (68° to 77°F).
Key facts
- Active ingredient (INN)
- Lincomycin
- Brand
- Lincocin
- Strength
- 600 mg/2 mL
- Dosage form
- Injection
- Route
- Intramuscular, intravenous, subconjunctival
- Packs
- 1 vial of 2 mL
- Marketing authorisation holder
- Pharmacia & Upjohn
- Manufacturer
- Pharmacia & Upjohn
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature 20° to 25°C (68° to 77°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01FF02 Lincomycin
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 18 August 2023
- Identifiers
- RxCUI 102787, 239212DailyMed set ID c01906fa-2c73-4c13-9765-2fd06628d263NDC 0009-0104Application NDA050317
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 2 mL in 1 vial | 0009-0104-04 | Pharmacia & Upjohn | 18 August 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 December 1964 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Lincomycin 600 mg/2 mL injection.
Other strengths and forms of Lincomycin
Clinical summary
Lincomycin is a prescription medicine indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci, among other approved uses. It is available as injection for intramuscular, intravenous and subconjunctival use. MedsAcross supplies Lincomycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about LincomycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Lincocin prescribing information (Pharmacia & Upjohn) · U.S. National Library of Medicine, DailyMed
Need Lincocin 600 mg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.